Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.50 |
| ▸ | DRD3 | P35462 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 4/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 4/20 | 0.43 |
| ▸ | HTR1A | P08908 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8514471 | 0.85 | S1PR1 (0.42) | DRD2DRD3MAPTDRD4HTR1A | |
| SCHEMBL5915129 | 0.80 | HTR1A (0.54) | DRD2DRD3NPSR1HTR6DRD4 | |
| Hydrochloric Acid SCHEMBL18037806 | 0.78 | KDM4E (0.46) | MAPT | |
| SCHEMBL4554837 | 0.77 | WDR5 (0.41) | DRD2DRD3MAPTHTR6DRD4 | |
| SCHEMBL4554365 | 0.77 | KDM4E (0.44) | DRD2DRD3HTR6 | |
| SCHEMBL24170899 | 0.76 | DRD2 (0.57) | DRD2DRD3HTR6DRD4HTR1A | |
| SCHEMBL1355391 | 0.74 | ALDH1A1 (0.52) | MAPT | |
| SCHEMBL27977382 | 0.74 | HTR1A (0.52) | DRD2DRD3MAPTNPSR1HTR6 | |
| Dimethylamine SCHEMBL5863462 | 0.73 | DRD2 (0.49) | DRD2DRD3BACE1DRD4HTR1A | |
| SCHEMBL27861988 | 0.71 | DRD2 (0.40) | DRD2DRD3MAPTDRD4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050267126-A1 | Compounds derived from aryl carbamates, preparation thereof and uses of same | CEREP (FR) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267126-A1 | Compounds derived from aryl carbamates, preparation thereof and uses of same | HTR4, HTR2B, HTR1B | DRD2 96/4885DRD3 153/4885MAPT 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.